Linkedin Twitter
Contact

Connect to Cure

With its clinical-stage platform technology, Synaffix has established itself as the preferred technology provider enabling best-in-class targeted cancer therapeutics.

About Synaffix

Connect to Innovate

Centered entirely around the antibody glycan, Synaffix has established a simple, rapidly deployable technology platform, enabling any company with an antibody to develop a proprietary, best-in-class ADC or bispecific.

About the Platform

Connect to Partner

Under a focused technology out-licensing business model, Synaffix has delivered multiple best-in-class therapeutic candidates for our partners’ pipelines.

Collaborate with Synaffix
Next-Generation ADCs Being Developed Under License Agreements
Partner
Preclinical
Phase 1
Partner / Licensee
Preclinical
Phase 1
ADCT-601 (AXL-targeting)
ADCT-701 (DLK-1-targeting)
Partner / Licensee
Preclinical
Phase 1
XMT-1660 (B7-H4-targeting)
Partner / Licensee
JNJ_Logo_Shorthand_Red_RGB
in collaboration with Mersana Therapeutics, Inc.
Preclinical
Phase 1
Multiple Undisclosed
Partner / Licensee
Preclinical
Phase 1
MRG004A (TF-targeting)
Undisclosed
Partner / Licensee
Preclinical
Phase 1
IBI-343 (Claudin 18.2 targeting)
Undisclosed
Partner / Licensee
Preclinical
Phase 1
2x Undisclosed
Partner / Licensee
Preclinical
Phase 1
Undisclosed
Partner / Licensee
Preclinical
Phase 1
3x Undisclosed
Partner / Licensee
Preclinical
Phase 1
Undisclosed
Partner / Licensee
Preclinical
Phase 1
Undisclosed
Partner / Licensee
Preclinical
Phase 1
Undisclosed
Partner / Licensee
Preclinical
Phase 1
Undisclosed
Partner / Licensee
Preclinical
Phase 1
Undisclosed

News

Read All News >>

Connect

Contact Us
Meet Us at Events

Protein Conjugates

Bring your own and/or choose from the following categories. 

 

Just like our ADC technology, we can easily attach peptide and protein-based payloads to your antibody.

 

Early preclinical data available on request.

Bring Your Own

scFv / Fab
Cytokine

Immune Cell Recruiters

Anti-CD3

T cell recruitment
IL-15

NK cell recruitment

IL-15 Receptor Fusion

NK cell recruitment

HydraSpace® Polar Spacer

Forming an integral part of every toxSYN®

linker-payload, HydraSpace® bears a negative charge at physiological pH and improves:

  1. Therapeutic efficacy
  2. Tolerability
  3. PK
  4. Manufacturability
Key publication about HydraSpace
HydraSpace®

GlycoConnect™ design easily matches payload potency with the most appropriate drug-antibody ratio (DAR).

Key publications about GlycoConnect™

GlycoConnect™ ADCs
Metal-Free Click Conjugation
Enzymatic ADCs (Review)
DAR1 Drug Antibody Ratio 1:1
DAR1
Drug Antibody Ratio 1:1
DAR2 Drug Antibody Ratio 2:1
DAR2
Drug Antibody Ratio 2:1
DAR4 Drug Antibody Ratio 4:1
DAR4
Drug Antibody Ratio 4:1

toxSYN® Linker-Payloads

Choose from the following linker-payloads, attach to your antibody under a technology evaluation and go straight into ADC product development following positive POC.
DAR1 Drug Antibody Ratio 1:1
DAR1
Drug Antibody Ratio 1:1
DAR4 Drug Antibody Ratio 4:1
DAR4
Drug Antibody Ratio 4:1
DAR2 Drug Antibody Ratio 2:1
DAR2
Drug Antibody Ratio 2:1
toxSYN®
Linker-Payload		 Mode-of-Action Payload
(Active Catabolite)
1. SYNtecan E™*Topoisomerase 1 inhibitor Camptothecin-based
2. SYNeamicin D™*DNA
damaging agent		 Calicheamicin-based
3. SYNeamicin G™*
4. SYN-PNU™*Nemorubicin-based
5. SYNstatin E™Microtubule
inhibitors		 Auristatin-based
6. SYNstatin F™
7. SYNtansine™ Maytansine-based

* Patent protection filed by Synaffix, beyond the claims of GlycoConnect™ and HydraSpace®

** N-6-aminohexanoyl-maytansine (Ahx-maytansine)